Three Rivers Pharmaceuticals Signs Licensing Agreement With Amgen
Posted on: Thursday, 18 September 2008, 12:00 CDT
Three Rivers Pharmaceuticals, a privately held company that focuses on specialized therapies including hepatitis C therapies, has signed a definitive licensing agreement with Amgen to expand its commercial rights to the hepatitis C drug Infergen.
Three Rivers Pharmaceuticals will obtain commercial rights to Infergen in all markets except Japan. In addition, Three Rivers Pharmaceuticals will obtain commercial rights to China, effective March 31, 2009. Three Rivers Pharmaceuticals currently has commercial rights to Infergen in the US and Canada.
Three Rivers Pharmaceuticals will seek marketing partners to assist with the commercialization of Infergen outside of the US.
Infergen is indicated for the treatment of chronic hepatitis C virus (HCV)infection in patients 18 years of age or older with compensated liver disease who have anti-HCV serum antibodies or the presence of HCV RNA.
Patrick Kerrish, executive vice president of business development at Three Rivers Pharmaceuticals, said: "The expansion of commercial rights to Infergen compliments Three Rivers Pharmaceuticals strategy to continue to grow its hepatitis C franchise."
Source: Datamonitor
Related Articles
- Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference
- Transcept Pharmaceuticals to Hold Conference Call on Agreement with Purdue Pharmaceutical Products L.P. to Commercialize Intermezzo(R) in the United States
- Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
- Aethlon Medical Announces Data Supported Strategy to Increase Hepatitis-C (HCV) Cure Rates
- Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
- BioSante Pharmaceuticals Announces the Commercial Launch of Elestrin(TM)
- Peregrine Pharmaceuticals Plans HIV and Hepatitis C Trial
- Valeant Pharmaceuticals Initiates Infergen(R) Phase 4 Study
- Genelabs Announces Collaboration for Development and Commercialization of HCV Non-Nucleoside Drug Candidates
- OraSure Receives HCV Patent License From Ortho-Clinical Diagnostics and Chiron Corporation; OraSure to Develop and Commercialize Rapid HCV Test
 |
 |
User Comments (0)
RSS Feeds